Pressor response to beta-blocking drugs

M. G. Ziegler, L. C. Woodson

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    A patient with essential hypertension had a prolonged period of uncontrollable high blood pressure during therapy with the nonspecific beta-blocker nadolol. A subsequent challenge with the beta1-blocker atenolol caused a pressor response associated with diminished catecholamine release, impaired catecholamine clearance, loss of baroreflex response, and bradycardia. Beta-blocking drugs can lead to hypertension by causing fluid retention, reversal of catecholamine vasodilatation, or a direct pressor effect.

    Original languageEnglish (US)
    Pages (from-to)81-88
    Number of pages8
    JournalClinical Therapeutics
    Volume7
    Issue number1
    StatePublished - 1984

    Fingerprint

    Catecholamines
    Nadolol
    Pharmaceutical Preparations
    Hypertension
    Atenolol
    Baroreflex
    Bradycardia
    Vasodilation
    Therapeutics
    Essential Hypertension

    ASJC Scopus subject areas

    • Pharmacology

    Cite this

    Ziegler, M. G., & Woodson, L. C. (1984). Pressor response to beta-blocking drugs. Clinical Therapeutics, 7(1), 81-88.

    Pressor response to beta-blocking drugs. / Ziegler, M. G.; Woodson, L. C.

    In: Clinical Therapeutics, Vol. 7, No. 1, 1984, p. 81-88.

    Research output: Contribution to journalArticle

    Ziegler, MG & Woodson, LC 1984, 'Pressor response to beta-blocking drugs', Clinical Therapeutics, vol. 7, no. 1, pp. 81-88.
    Ziegler MG, Woodson LC. Pressor response to beta-blocking drugs. Clinical Therapeutics. 1984;7(1):81-88.
    Ziegler, M. G. ; Woodson, L. C. / Pressor response to beta-blocking drugs. In: Clinical Therapeutics. 1984 ; Vol. 7, No. 1. pp. 81-88.
    @article{8b56a667bf1e4ec39620f4a7340f2d31,
    title = "Pressor response to beta-blocking drugs",
    abstract = "A patient with essential hypertension had a prolonged period of uncontrollable high blood pressure during therapy with the nonspecific beta-blocker nadolol. A subsequent challenge with the beta1-blocker atenolol caused a pressor response associated with diminished catecholamine release, impaired catecholamine clearance, loss of baroreflex response, and bradycardia. Beta-blocking drugs can lead to hypertension by causing fluid retention, reversal of catecholamine vasodilatation, or a direct pressor effect.",
    author = "Ziegler, {M. G.} and Woodson, {L. C.}",
    year = "1984",
    language = "English (US)",
    volume = "7",
    pages = "81--88",
    journal = "Clinical Therapeutics",
    issn = "0149-2918",
    publisher = "Excerpta Medica",
    number = "1",

    }

    TY - JOUR

    T1 - Pressor response to beta-blocking drugs

    AU - Ziegler, M. G.

    AU - Woodson, L. C.

    PY - 1984

    Y1 - 1984

    N2 - A patient with essential hypertension had a prolonged period of uncontrollable high blood pressure during therapy with the nonspecific beta-blocker nadolol. A subsequent challenge with the beta1-blocker atenolol caused a pressor response associated with diminished catecholamine release, impaired catecholamine clearance, loss of baroreflex response, and bradycardia. Beta-blocking drugs can lead to hypertension by causing fluid retention, reversal of catecholamine vasodilatation, or a direct pressor effect.

    AB - A patient with essential hypertension had a prolonged period of uncontrollable high blood pressure during therapy with the nonspecific beta-blocker nadolol. A subsequent challenge with the beta1-blocker atenolol caused a pressor response associated with diminished catecholamine release, impaired catecholamine clearance, loss of baroreflex response, and bradycardia. Beta-blocking drugs can lead to hypertension by causing fluid retention, reversal of catecholamine vasodilatation, or a direct pressor effect.

    UR - http://www.scopus.com/inward/record.url?scp=0021710738&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0021710738&partnerID=8YFLogxK

    M3 - Article

    VL - 7

    SP - 81

    EP - 88

    JO - Clinical Therapeutics

    JF - Clinical Therapeutics

    SN - 0149-2918

    IS - 1

    ER -